Cat. No.: DAB-0011899
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu308 of human ChREBP isoform α protein. The sequence surrounding this region is 100% conserved in all known isoforms of ChREBP. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | MLXIPL |
| UniProt No. | Q9NP71 |
| Gene ID | 51085 |
| Gene Description | Carbohydrate-responsive element-binding protein is a glucose-responsive transcription factor that regulates glycolytic and lipogenic gene expression. High levels of glucose induce the transcriptional activity of ChREBP. ChREBP is most abundant in tissues of de novo lipogenesis and forms a heterotetramer with its binding partner MLX to bind to the promoter regions of its target genes. ChREBP regulates fatty acid synthesis, glucose homeostasis and insulin sensitivity in white adipose tissue. In white adipose tissue, ChREBP isoform α activates the expression of the potent ChREBP isoform β in a glucose-dependent manner. ChREBP-β expression levels predict insulin sensitivity in human white adipose tissue. In addition, research studies have shown that Akt2 induces the transcriptional activity of ChREBP-β to stimulate de novo lipogenesis in brown adipose tissue for fuel storage. Furthermore, ChREBP-β is a potent activator of lipogenesis in the liver. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
